Unlike the sweeping generalizations by politicians and media that knocked the biotech sector back on its heels, this piece from Woodford shows discernment and doesn't lump the Valeants in with NWBO or other real R&D companies. Why has Neil Woodford beat the market for the past 25 years? He thinks for himself.